199 related articles for article (PubMed ID: 12100936)
1. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.
Oefelein MG; Ricchiuti VS; Conrad PW; Goldman H; Bodner D; Resnick MI; Seftel A
Urology; 2002 Jul; 60(1):120-4. PubMed ID: 12100936
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
Shulman MJ; Karam JA; Benaim EA
Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
[TBL] [Abstract][Full Text] [Related]
4. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
5. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
6. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
7. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
11. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
13. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
Kitagawa Y; Ueno S; Izumi K; Mizokami A; Hinotsu S; Akaza H; Namiki M
J Cancer Res Clin Oncol; 2014 Apr; 140(4):673-9. PubMed ID: 24522405
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
15. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
16. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.
Hanlon AL; Diratzouian H; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):297-303. PubMed ID: 12023133
[TBL] [Abstract][Full Text] [Related]
18. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
[TBL] [Abstract][Full Text] [Related]
19. Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.
Hanlon AL; Horwitz EM; Hanks GE; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):43-52. PubMed ID: 14697419
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]